You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RECIST 1.1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Patient in a Metastatic Stage Eligible for First-line Treatment With Immune Checkpoint Inhibitor Trial in Boulogne

Recruiting
  • NSCLC Patient in a Metastatic Stage Eligible for First-line Treatment With Immune Checkpoint Inhibitor
  • assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.
  • Boulogne Billancourt, France
  • +2 more
Jul 12, 2021

Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 Trial in

Recruiting
  • Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
  • Biological : Toripalimab Drug: Axitinib
  • sunitinib
  • Beijing, China
    Beijing Cancer Hospital
Jan 24, 2021

Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1

Completed
  • Poorly Differentiated Malignant Neuroendocrine Carcinoma
  • +4 more
  • Everolimus (Afinitor®)
  • Berlin, Germany
    Charité-Universitätsmedizin, Medizinische Klinik m. S. Hepatolog
Oct 27, 2020

Fibrolamellar Hepatocellular Carcinoma Trial in Baltimore (Durvalumab, DRP-104)

Not yet recruiting
  • Fibrolamellar Hepatocellular Carcinoma
  • Baltimore, Maryland
    Johns Hopkins SKCCC
Aug 30, 2023

NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sacituzumab Govitecan
  • Pembrolizumab
  • Marietta, Georgia
  • +2 more
Jan 27, 2023

Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma Trial in Aurora (Nab-paclitaxel,

Withdrawn
  • Triple Negative Breast Cancer
  • +4 more
  • Aurora, Colorado
    University of Colorado Hospital
Dec 2, 2022

Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer Trial in Germany, Spain, United Kingdom (Pembrolizumab, Cisplatin,

Active, not recruiting
  • Biliary Tract Cancer
  • +3 more
  • Leipzig, Germany
  • +6 more
Jul 1, 2022

Small Cell Lung Cancer Trial in Worldwide (biological, drug, radiation)

Recruiting
  • Small Cell Lung Cancer
  • Pembrolizumab 200 mg
  • +8 more
  • Chandler, Arizona
  • +170 more
Feb 2, 2023

Lung Cancer Trial in Tianjin (PD-1 inhibitor, PARP inhibitor)

Recruiting
  • Lung Cancer
  • PD-1 inhibitor
  • PARP inhibitor
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
May 23, 2022

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

Endometrial Cancer Trial (MK-2870, Doxorubicin, Paclitaxel)

Not yet recruiting
  • Endometrial Cancer
  • MK-2870
  • +2 more
  • (no location specified)
Nov 10, 2023

Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer Trial in Australia, Belgium,

Recruiting
  • Recurrent Ovarian Cancer
  • +2 more
  • Birmingham, Alabama
  • +14 more
Oct 11, 2022

NSCLC Trial in China (Pembrolizumab, Lenvatinib, Placebo for lenvatinib)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +2 more
  • Hefei, Anhui, China
  • +16 more
Oct 14, 2022

For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment

Not yet recruiting
  • For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method
  • Shenyang, Liaoning, China
    Liaoning Tumor Hospital & Institute
Mar 7, 2023

Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Tumors Trial in Worldwide (biological, drug, other)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Pembrolizumab
  • +4 more
  • Phoenix, Arizona
  • +178 more
Jan 25, 2023

Uveal Melanoma Trial in Minneapolis (PAC-1, Entrectinib)

Active, not recruiting
  • Uveal Melanoma
  • Minneapolis, Minnesota
    HealthPartners Institute Regions Cancer Care Center
Nov 15, 2022

Hepatocellular Carcinoma Trial in Worldwide (lenvatinib, pembrolizumab (200 mg))

Completed
Has Results
  • Hepatocellular Carcinoma
  • San Francisco, California
  • +25 more
Jan 13, 2023

Squamous Cell Carcinoma Trial (MK-3475A)

Not yet recruiting
  • Squamous Cell Carcinoma
  • MK-3475A
  • (no location specified)
Sep 11, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in United States (REGN5668, Cemiplimab, REGN4018)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Duarte, California
  • +7 more
Sep 26, 2022

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

Recruiting
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Lyon, France
    Centre Léon Bérard
Nov 30, 2022

Prostate Cancer Metastatic Trial (MK-5684, Abiraterone acetate, Enzalutamide)

Not yet recruiting
  • Prostate Cancer Metastatic
  • (no location specified)
Nov 21, 2023

Melanoma Trial in Worldwide (Talimogene Laherparepvec, Pembrolizumab, Placebo)

Terminated
Has Results
  • Melanoma
  • Talimogene Laherparepvec
  • +2 more
  • Birmingham, Alabama
  • +160 more
Nov 10, 2022

Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)

Recruiting
  • Locally Advanced Cervical Cancer
  • Villejuif, Val De Marne, France
    Gustave Roussy
Feb 15, 2022

Relapsed/Refractory Small Cell Lung Cancer Trial in Worldwide (Tarlatamab)

Recruiting
  • Relapsed/Refractory Small Cell Lung Cancer
  • Birmingham, Alabama
  • +78 more
Jan 18, 2023

Colorectal Cancer Trial in Shanghai (FOLFIRI+Bevacizumab)

Recruiting
  • Colorectal Cancer
  • Shanghai, Pudong, China
    Affiliated Cancer Hospital of Fudan University
Jul 24, 2023